Syngene International (NSE:SYNGENE) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:SYNGENE Syngene International Ltd NSE:SYNGENE
81 GF Score
Price ₹440.00
GF Value ₹788.92
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Syngene International Research & Development?

Syngene International NSE:SYNGENE +0.02% 81 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SYNGENE with a GF Score™ of 81/100 and a GF Value™ of ₹788.92 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Syngene International's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Syngene International  (NSE:SYNGENE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Syngene International Research & Development Related Terms

Syngene International Research & Development Historical Data

* Premium members only.

The historical data trend for Syngene International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syngene International Research & Development Chart

Syngene International Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syngene International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SYNGENE
81GF Score
Syngene International Ltd NSE:SYNGENE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syngene International Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Syngene International (NSE:SYNGENE) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Syngene International and its competitors.
Is Syngene International's Research & Development too high?
Syngene International's current Research & Development is ₹0 Mil. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Research & Development compare to TMO and DHR?
Syngene International's Research & Development of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Syngene International and its competitors. Syngene International's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹788.92, compared to a current price of ₹440.00 — trading 44.2% below its estimated fair value. The current Research & Development is ₹0 Mil. Syngene International's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syngene International (NSE:SYNGENE) Overvalued in 2026?

Based on GuruFocus' analysis, Syngene International stock appears to be undervalued. The current stock price of ₹440.00 is trading 44.2% below its estimated GF Value™ of ₹788.92. GuruFocus considers Syngene International to be Significantly Undervalued.

Key valuation signals for NSE:SYNGENE:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹788.92 vs. price of ₹440.00 (44.2% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syngene International Business Description

Other Exchanges 539268:India
Address Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score

Get the complete analysis for NSE:SYNGENE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹440.00
Price
₹788.92
GF Value